News
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback